Parkview Health

Parkview Health Research Repository
Pharmacy

Parkview Research Center

2020

Characterization of antibiotic use and culture data in COVID-19
pandemic patients
Ashley Logan PharmD
Stacy Clore PharmD, BCPS
Alissa Keillor PharmD

Follow this and additional works at: https://researchrepository.parkviewhealth.org/pharma
Part of the Pharmacy and Pharmaceutical Sciences Commons

Characterization of antibiotic use and culture data in COVID-19
pandemic patients
Ashley Logan, PharmD | Stacy Clore, PharmD, BCPS | Alissa Keillor, PharmD
Parkview Regional Medical Center | Fort Wayne, Indiana

RESULTS

OBJECTIVE

Percentage of Respiratory Coinfections
21, 6%

Number of Antibiotics Initiated

Most Common Antibiotic Regimens Initiated

5, 1%
200

• COVID-19 is an infection caused by a novel coronavirus (SARS-CoV-2) causing a
respiratory infection that can be spread easily from person-to-person.
• Bacterial and viral coinfections have been studied and are well-known in relation to
other viral infections, such as influenza.1
• Current literature has shown little association between bacterial, viral or fungal coinfections with COVID-19.2,3,4
• Recently, a survey completed around the world found that only 29.1% of providers
elected to not prescribe initial antibiotics for patients presenting with COVID-19.
o Most providers initiated therapy to cover for Staphylococcus aureus, a pathogen
that is known to cause bacterial superinfection in patients with influenza.5
• The Infectious Disease Society of America suggests that the benefits of starting
antimicrobial therapy early in patients with COVID-19 may not outweigh the risks
of increased bacterial resistance.6

METHODS
• Retrospective chart review conducted on inpatients with confirmed COVID-19 from
March 1, 2020 to August 5, 2020
• Inclusion Criteria: Positive COVID-19 polymerase chain reaction (PCR) test and
received antibiotics while admitted to the facility
• Exclusion Criteria: Initiation of antibiotics for reasons other than relating to the
concern for possible coinfection with COVID-19
• Primary Outcome: Prevalence of patients with bacterial, viral or fungal
respiratory coinfections
o Cultures within the first 48 hours of admission were included in the analysis
• Secondary Outcomes:
i. Co-infectious organisms identified
ii. Mechanical ventilation requirement
iii. Inpatient mortality
iv. Empiric antibiotic regimens used
v. Duration of inpatient antibiotic therapy

RESULTS
Baseline Characteristics
Characteristic
Age (n, %)

Male (n, %)
Female (n, %)

n = 373
0 – 17 years
18 – 64 years
> 65 years

7 (1.9%)
167 (44.8%)
199 (53.4%)
190 (50.9%)
183 (49.1%)

168,
45%

93,
25%

184,
49%

180

274,
74%

Ceftriaxone/ Azithromycin

100

*coinfections include: 15 bacterial, 5 viral, and 1 fungal

47

Ceftriaxone/ Azithromycin

6

Levofloxacin
25

18

17

0

Piperacillin-tazobactam

5
3
3
2
2
2
2

Fungal (n)
Aspergillus niger

2
1
2
1

1

†Bacterial pathogens identified in only one patient: Providencia startii, Acinetobacter baumannii, Streptococcus pneumoniae, Serratia marcescens, Enterobacter
cloacae, Mycobacterium fortuitum

Secondary Outcomes Related to Presence of Coinfection
Non-respiratory
Coinfections
(n = 81)

Respiratory
Coinfections
(n = 21)

Without
Detected
Coinfection
(n = 271)
6.2 (3.2 – 10.9)

Duration of
7.4 (4.8 – 13.7)
12.3 (4.6 – 19.2)
Hospitalization
(median days, IQR)
Type of Coinfection*
(n, %)
Bloodstream
35 (43.2%)
4 (19.0%)
n/a
Urinary Tract
46 (56.8%)
7 (33.3%)
n/a
Other†
10 (12.3%)
0 (0.0%)
n/a
Laboratory Values±
(median, IQR)
8.2 (4.1 – 12.5)
6.8 (5.2 – 9.0)
WBC 7.3 (4.1 – 10.7)
8.5 (3.2 – 21.1)
8.5 (4.9 – 15.2)
CRP 14.1 (6.9 – 20.1)
0.15 (0.09 – 0.29)
Procalcitonin 0.28 (0.15 – 0.63) 0.19 (0.13 – 0.91)
Temperature 99.2 (98.2 – 101.4) 99.4 (98.6 – 100.2) 99.5 (98.6 – 101.0)
Ventilator Use¥ (n, %)
28 (27.5%)
12 (57.14%)
38 (14.0%)

20/102 (19.6%)

6/21 (28.6%)

*Including patients with more than one detected coinfection.
†Other infections including wounds (abdominal, amputation, etc.), liver abscess, intra-abdominal infection, C. difficile
±Laboratory values collected on admission
¥Patients requiring mechanical ventilation at any point during their admission

30/271 (11.1%)

Any
Coinfection

6.9

Respiratory
Coinfection

5

4.2
4
3

No
Coinfection

2
1

Other antibiotics initiated either monotherapy or in combination: doxycycline, meropenem,
ertapenem, ampicillin/ampicillin-sulbactam, cefepime, aztreonam, clindamycin, linezolid,
gentamicin, metronidazole, amoxicillin-clavulanate and cephalexin.

Pathogens Identified in Patients with a Positive Respiratory Culture

Staphylococcus aureus (MSSA)
Staphylococcus aureus (MRSA)
Klebsiella pneumoniae
Haemophilus influenzae
Escherichia coli
ESBL Escherichia coli
Pseudomonas aeruginosa

7

One patient was initiated on four different antibiotic therapies.

Pathogen
Viral (n)
Coronavirus (NL63)
Coronavirus (OC43)
Influenza B
Rhinovirus/
Enterovirus

9

Vancomycin/ Piperacillintazobactam

80

20

9

8

120

40

Single Antibiotic Therapy
Dual Antibiotic Therapy
Triple Antibiotic Therapy

No Respiratory Culture Collected
Negative Respiratory Culture
Positive Respiratoy Culture*

Inpatient Mortality
(n, %)

180

140

60

Pathogen
Bacterial† (n)

10

160

Patients (n)

BACKGROUND

Duration of Antibiotic Use

Days

The objective of this study was to identify the prevalence of bacterial, viral, or fungal
coinfections and to describe the empiric antimicrobial regimens in patients with
confirmed COVID-19.

RESULTS

0

DISCUSSION & CONCLUSIONS
• Out of the 373 patients included in the study, 189 patients (51%) were tested for a
respiratory coinfection, with 21 of those patients (11.1%) testing positive for a detected
respiratory pathogen.
• The low number of identified respiratory coinfections and baseline characteristics (i.e.
WBC) indicates that empiric antibiotics for a respiratory coinfection are likely not needed
upon admission. However, clinical correlation with chest x-ray and possible sputum
production is warranted.
o In patients with a suspected respiratory coinfection, the culture data suggests that
ceftriaxone monotherapy would be an appropriate empiric regimen.
o Of note, it is unknown if the bacterial pathogens identified in the respiratory cultures
were responsible for a secondary infection, were contaminants, or if they were
colonizers of the respiratory tract.
• It appears that patients with respiratory coinfections on admission were more likely to
need mechanical ventilation and had a higher rate of mortality during their hospital
admission than those without a respiratory coinfection, indicating the dangers of
bacterial superinfections with COVID-19. However, this data does not reflect additional
coinfections that may have been acquired during their hospitalization.
• Lastly, the findings suggested that we currently have de-escalation strategies in place to
prevent unnecessary use of antibiotics, as patients without a coinfection had shorter
durations of antibiotic use. It is recommended that pharmacists and physicians continue
to diligently eliminate unnecessary antibiotic therapy earlier on in the course to avoid
unnecessary exposure.
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